Statins are associated with a reduced risk of bone fracture in hemodialysis (HD) patients

Nichols, Robert B.; Hopman, Wilma M.; Morton, A. Ross; Harman, Gavin J.; Holden, Rachel M.

doi:10.1111/j.1542-4758.2008.00265.x

Cited by 6 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Statin therapy in CKD‐5D was analyzed in the DOPPS database for its protective effect on fractures but no association was found (15). Only one retrospective cohort of 174 HD patients in Canada has recently reported a significant negative association between bone fractures and statin therapy (26).…”

Section: Treatment Optionsmentioning

confidence: 99%

“…Fragility fractures generally require a bone with reduced strength being exposed to an impact, usually resulting from a fall. Risk factors consistently associated with an increased risk of fracture for patients on dialysis include older age, female gender, previous renal transplant, and duration of dialysis (Table 1) (15,16,(24)(25)(26)(27), but there is little information on the influence of ROD on fracture risk.…”

Section: Risk Factors For Fracturementioning

confidence: 99%

See 1 more Smart Citation

A Rational Guide to Reducing Fracture Risk in Dialysis Patients

Toussaint

Elder

Kerr

2010

Seminars in Dialysis

View full text Add to dashboard Cite

Extrapolation of evidence-based management of disorders in the general population to patients with chronic kidney disease (CKD) is not always appropriate, and the prevention of bone fracture and reduction of fracture risk in CKD stages 3-5 is one example. Compared to the general population, fracture risk is greater in CKD patients, especially those on dialysis (CKD-5D). Fractures in CKD-5D are associated with a marked increase in morbidity and mortality and with an aging dialysis population the burden of disease caused by fracture is likely to increase. Patients with CKD-5D have distinct risks for fracture, as well as sharing risks identified in the general population. The development of the CKD mineral and bone disorder constitutes a significant cause for these differences. Literature addressing the determination of fracture risk and the efficacy of treatments to reduce fracture in patients on dialysis is limited. While some tools used for the diagnosis and monitoring of osteoporosis are applicable to patients on dialysis, bone mineral density measurement by dual-energy X-ray absorptiometry is generally not helpful and therapeutic interventions that reduce fracture risk in the nonuremic population cannot be generalized to patients on dialysis. This review outlines available evidence on the incidence, risk factors, and management of fractures in CKD-5D with recommendations for strategies to reduce fracture risk.

show abstract

Section: Treatment Optionsmentioning

confidence: 99%

Section: Risk Factors For Fracturementioning

confidence: 99%

A Rational Guide to Reducing Fracture Risk in Dialysis Patients

Toussaint

Elder

Kerr

2010

Seminars in Dialysis

View full text Add to dashboard Cite

show abstract

“…Although relatively abundant information about simvastatin indicates its possible beneficial effect on bone [6,7],whether simvastatin could prevent the bone loss in tail-suspended rat is still unknown. Therefore, the present study was performed to establish the rat model of simulated unloading and investigate the effects of simvastatin on bone mass, microarchitecture and bone formation/resorption activities in tail-suspended rat.…”

Section: Introductionmentioning

confidence: 99%

Simvastatin Partially Prevents Bone Loss in Tail-suspended Rat:Bone Mineral Density and Histomorphometry Analysis

Tian¹,

Fan²,

Liu³

et al. 2014

Proceedings of the 2014 International Conference on Computer, Communications and Information Technology

View full text Add to dashboard Cite

Background: Skeletal unloading induces osteopenia in the loaded bones. Simvastatin, as one of the HMG-CoA reductase inhibitors for lowering lipids, has been demonstrated its potential benefit in bone formation, while no study reported whether simvastatin could prevent the bone loss in unloaded bone. Objective: We performed this study to assess the effect of simvastatin on bone mass and bone formation in tail-suspension rat. Methods: Tailsuspension rats were treated with or without simvastatin for 3 weeks, The right femurs were removed for the measurement of bone histomorphometry after bone mineral density(BMD) assessment by dual-energy X-ray absorptiometry. Results: The total bone mineral density(tBMD) and distal bone mineral density(dBMD) of tailsuspended rats were significantly lower than that of normal rat, while proximal bone mineral density(pBMD) of normal rats was significantly higher than tail-suspended rat, but no statistical difference was observed between normal and simvastatin-treatment rats. Similar to the BMD results, histomorphometric assessment for the trabeculae bone of distal femurs showed markedly higher BV/TV and lower trabecular Tb. Sp in normal rats compared to those of tailsuspended rats, while both the bone formation and bone resorption parameters were markedly increased in tail-suspended rats with or without simvastatin treatment, simvastatin showed stimulation on osteoid formation comparing to normal and tail-suspended rats. Conclusion: simvastatin treatment could partially prevent tailsuspention-induced osteoporosis in unloaded limb.

show abstract